ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com

StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research report sent to investors on Tuesday.

Several other analysts have also issued reports on the company. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a “buy” rating and a $80.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Finally, JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Trading Down 5.9 %

Shares of ANIP stock opened at $63.05 on Tuesday. The business has a 50-day moving average price of $61.73 and a two-hundred day moving average price of $58.86. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.00. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.37 billion, a P/E ratio of -114.64 and a beta of 0.49.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the sale, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,200 shares of company stock worth $191,776. 12.70% of the stock is currently owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE increased its position in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the period. KBC Group NV lifted its position in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $200,000. Finally, Bridgefront Capital LLC purchased a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $204,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.